🟢 BioNTech is trading 5% up today after Q3 revenue beat and higher 2026 guidance

BioNTech is trading at $91.10, up 4.81%, after its Q3 results beat expectations.

• November 3 results included €1.29 billion in Q3 revenue, above consensus, and raised 2026 revenue guidance to €1.7–€1.9 billion.
• A €613 million BMS pumitamig milestone helped drive the beat, while COVID-19 vaccine revenue declined year over year.
• Biotech XBI is up 2.13% during the regular session, which may also support the move; the earnings release is the clearest company-specific catalyst.